Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:BABY

Natus Medical (BABY) Stock Price, News & Analysis

Natus Medical logo

About Natus Medical Stock (NASDAQ:BABY)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
$26.75
$31.92
52-Week Range
N/A
Volume
22 shs
Average Volume
165,325 shs
Market Capitalization
$1.12 billion
P/E Ratio
23.21
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders. The company also provides computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology; and software systems for managing and tracking disorders and diseases for public health laboratories. In addition, it offers electroencephalography, long term monitoring, intensive care unit monitoring, electromyography, sleep analysis or polysomnography, and intra-operative monitoring solutions. Further, the company provides hearing screening products; diagnostic hearing assessment products to screen for/or diagnose hearing loss, or to identify abnormalities affecting the peripheral and central auditory nervous systems; balance and mobility systems to diagnose and assist in treating balance disorders; and thermoregulation products to control the incubators and warmers. Additionally, it offers jaundice management products; brain injury products; NICVIEW, a live streaming video for families with babies in the neonatal intensive care unit (NICU); essential products used in the everyday operation of NICU; and eye imaging systems and products used in the advanced science and practice of neonatal and pediatric retinal imaging. The company also provides computer-based audiological, otoneurologic, and vestibular instrumentation and sound rooms to hearing and balance care professionals. It serves hospitals, clinics, laboratories, physicians, nurses, audiologists, and governmental agencies. Natus Medical Incorporated was incorporated in 1987 and is headquartered in Pleasanton, California.

Remove Ads

Natus Medical Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
35th Percentile Overall Score

BABY MarketRank™: 

Natus Medical scored higher than 35% of companies evaluated by MarketBeat, and ranked 781st out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Natus Medical.

  • Earnings Growth

    Earnings for Natus Medical are expected to grow by 24.41% in the coming year, from $1.27 to $1.58 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Natus Medical is 23.21, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 22.56.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Natus Medical is 23.21, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 23.37.

  • Short Interest

    There is no current short interest data available for BABY.
  • Dividend Yield

    Natus Medical does not currently pay a dividend.

  • Dividend Growth

    Natus Medical does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for BABY.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Natus Medical this week, compared to 1 article on an average week.
  • Search Interest

    1 people have searched for BABY on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Natus Medical insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.65% of the stock of Natus Medical is held by insiders.

  • Percentage Held by Institutions

    91.56% of the stock of Natus Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Natus Medical's insider trading history.
Receive BABY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Natus Medical and its competitors with MarketBeat's FREE daily newsletter.

BABY Stock News Headlines

Don’t buy TSLA stock until you see this
After a surprise all-hands meeting, Elon Musk urged everyone to “hang onto your stock”... Sparking a rebound of around 10% on Tesla (TSLA) stock this past Monday. Leaving many investors pondering whether or not to buy into a position. That is exactly why I am stepping forward this Sunday, March 30th at 1 PM ET.
See More Headlines

BABY Stock Analysis - Frequently Asked Questions

Natus Medical Inc (NASDAQ:BABY) released its earnings results on Wednesday, October, 24th. The medical equipment provider reported $0.40 EPS for the quarter, missing the consensus estimate of $0.42 by $0.02. Natus Medical's quarterly revenue was up 6.5% compared to the same quarter last year.

Natus Medical (BABY) raised $9 million in an initial public offering on Wednesday, March 8th 2023. The company issued 1,766,618 shares at $5.00 per share.

Based on aggregate information from My MarketBeat watchlists, some other companies that Natus Medical investors own include Bristol-Myers Squibb (BMY), Meta Platforms (META), Starbucks (SBUX), Intel (INTC), Walt Disney (DIS), Gilead Sciences (GILD) and Activision Blizzard (ATVI).

Company Calendar

Last Earnings
10/24/2018
Today
3/28/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Electromedical Equipment
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:BABY
Fax
N/A
Employees
1,729
Year Founded
N/A

Profitability

Trailing P/E Ratio
23.21
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-22,930,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$530.89 million
Price / Cash Flow
9.39
Book Value
$11.80 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$1.12 billion
Optionable
Optionable
Beta
0.57
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:BABY) was last updated on 3/29/2025 by MarketBeat.com Staff
From Our Partners